Welcome to Oncogene!


Oncogene publishes the latest developments in cancer research, in particular: cellular oncogenes and their mechanism of activation; structure and function of encoded proteins; oncogenes of DNA and RNA tumor viruses; molecular oncology of human tumors; tumor suppressor genes; growth regulatory genes; cell cycle control; growth factors and receptors; apoptosis; immortalization and cellular senescence.

Impact Factor: 7.932*

Submit to Oncogene.
*2015 Journal Citation Reports® (Thomson Reuters, 2016)

Free online issue

Volume 35, No 50
15 December 2016

ISSN: 0950-9232
EISSN: 1476-5594

2015 Impact Factor 7.932*
15/213 Oncology
12/165 Genetics & Heredity
24/289 Biochemistry & Molecular Biology
25/187 Cell Biology

Editors-in-chief:
Douglas R Green, USA
Justin Stebbing, UK

*2015 Journal Citation Reports® Science Edition (Thomson Reuters, 2016)

News

Post a video summary of your research
The Oncogene Journal is pleased to announce that authors can now upload video presentations to accompany their article when published. Presentations should provide a short, succinct summary of the research and be uploaded as Supplementary Material. Whilst enhancing reader experience, video summaries also provide an excellent tool for promotion to help increase visibility and reach. Please refer to the journal's Instructions for Authors for technical specifications.

Thank you to our reviewers
We would like to thank all those who took the time to review for Oncogene in 2015. The journal could not exist without the knowledge and critical evaluation that our reviewers provide. Your generosity is much appreciated, and we hope your association with the journal continues in future. Please check the list of reviewers in full.

A study of ovarian cancer in mice demonstrates that oncogenesis through fluctuation in the expression levels of certain proteins negates extracellular stimulation or mutation and defines them as novel prognostic markers in ovarian cancer. Read the article, or see coverage in the Times of India.

A report that mammary tumor cells undergoing epithelial–mesenchymal transition (EMT) in response to transforming growth factor-β (TGF-β1) become activated for targeted migration through the lymphatic system, similar to dendritic cells during inflammation, suggests that p38 MAP kinase inhibition may be a useful strategy to inhibit EMT and lymphogenic spread of tumor cells. Read the article, or the institution's press release.

'Open' option for authors
Oncogene offers authors the option to publish their articles with immediate open access upon publication. Open access articles will also be deposited on PubMed Central at the time of publication and will be freely available immediately. Find out more from our FAQs page.

Extra navigation

26 December 2016

natureevents

ADVERTISEMENT